Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2026)

Catalyst Pharmaceuticals filings provide 6 years of Long-Term Investments readings, the most recent being $27.3 million for Q1 2026.

  • On a quarterly basis, Long-Term Investments rose 12.71% to $27.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $27.3 million, a 12.71% increase, with the full-year FY2025 number at $22.5 million, up 4.51% from a year prior.
  • Long-Term Investments hit $27.3 million in Q1 2026 for Catalyst Pharmaceuticals, up from $22.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $27.3 million in Q1 2026 to a low of $12.9 million in Q3 2023.
  • Median Long-Term Investments over the past 4 years was $19.2 million (2025), compared with a mean of $19.0 million.
  • The widest YoY moves for Long-Term Investments: up 62.47% in 2025, down 4.51% in 2025.
  • Catalyst Pharmaceuticals' Long-Term Investments stood at $16.5 million in 2023, then soared by 30.78% to $21.6 million in 2024, then grew by 4.51% to $22.5 million in 2025, then rose by 21.08% to $27.3 million in 2026.
  • The last three reported values for Long-Term Investments were $27.3 million (Q1 2026), $22.5 million (Q4 2025), and $19.2 million (Q3 2025) per Business Quant data.